#

Key takeaways

• Tempus announced FDA 510(k) clearance for ECG-MR on September 28, 2026.

• The software analyzes standard 12-lead ECGs and looks for signs linked to moderate or severe mitral regurgitation.

• It is intended for a specific older patient population and is not a stand-alone diagnostic tool.

• Tempus says ECG-MR is its fourth FDA-cleared ECG-AI product.

• The clearance statement does not establish patient outcomes or broader clinical performance.

What Tempus announced

Tempus AI said the U.S. Food and Drug Administration granted 510(k) clearance to Tempus ECG-MR. The company describes it as software that analyzes standard, resting, non-ambulatory 12-lead electrocardiograms. It is designed to detect signs associated with moderate or severe mitral regurgitation.

Mitral regurgitation is a condition in which blood flows backward through the mitral valve. Tempus says ECG-MR gives a binary output for clinician interpretation. The announcement frames the product as a decision-support tool, not a final diagnosis.

Intended use and patient group

Tempus says the indicated population is patients aged 65 or older. These patients should be at risk of cardiovascular disease, have no prior diagnosis of moderate or severe mitral regurgitation, and have had no mitral valve intervention.

The company says relevant risk factors can include coronary artery disease, hypertension, obesity, or diabetes. It also mentions certain symptoms, but the announcement does not list them in detail. Because the source does not provide more specifics, those symptoms remain unspecified here.

Important limitations

Tempus states that ECG-MR is not intended to be a stand-alone diagnostic tool. It should not be used for serial monitoring. It should also not be used on ECGs with paced rhythms.

The company says clinicians should interpret the result together with the original ECG and other diagnostic information. It also says patient symptoms and clinical history should be part of the review. These limits matter because the product is meant to support, not replace, clinical judgment.

The clearance statement does not itself establish patient outcomes or clinical performance beyond the product's stated intended use. That means the announcement confirms regulatory clearance for a defined software use case. It does not, by itself, prove broader effectiveness.

Tempus's ECG-AI portfolio

Tempus says ECG-MR is its fourth FDA-cleared ECG-AI product. The company says this adds valvular disease to a portfolio that already spans arrhythmia, heart function, and pulmonary vascular disease.

This is a portfolio claim from Tempus's announcement. The source does not provide additional product names or comparative details. It also does not describe how the products are used together in practice.

Why the clearance matters

The announcement shows that ECG analysis software continues to expand into more specific clinical questions. In this case, the target is moderate or severe mitral regurgitation in a defined older population. The product uses a binary output, which suggests a simple result format for clinician review.

At the same time, the source is careful about scope. It limits use to a specific population and excludes paced rhythms. It also warns against using the software as a stand-alone diagnostic or for serial monitoring.

Morocco relevance

The source reports no Morocco-specific fact or availability. For readers, the global lesson is that regulatory clearance can be narrow. Product claims, intended use, and clinical limits should be checked carefully before any local evaluation.

Bottom line

Tempus's announcement is about regulatory clearance, not a broad clinical rollout. ECG-MR is positioned as an ECG-based software tool for a specific older patient group at risk of cardiovascular disease. Its role is to support clinician interpretation, not replace it.

The key point is the product's defined scope. Tempus says the software should be used with other clinical information and not as a stand-alone test. That makes the clearance important, but also clearly bounded.